Transforming Growth Factor-β1 (TGF-β1) Regulates Cell Junction Restructuring via Smad-Mediated Repression and Clathrin-Mediated Endocytosis of Nectin-like Molecule 2 (Necl-2)

Ying Gao, Wing-Yee Lui

School of Biological Sciences, The University of Hong Kong, Hong Kong, P.R.China

Abstract

Nectin-like molecule-2 (Necl-2), a junction molecule, is exclusively expressed by spermatogenic cells. It mediates homophilic interaction between germ cells and heterophilic interaction between Sertoli and germ cells. Knockout studies have shown that loss of Necl-2 causes male infertility, suggesting Necl-2-based cell adhesion is crucial for spermatogenesis. Transforming growth factor-βs (TGF-βs) are crucial for regulating cell junction restructuring that are required for spermatogenesis. In the present study, we aim to investigate the mechanism on how TGF-β1 regulates Necl-2 expression to achieve timely junction restructuring in the seminiferous epithelium during spermatogenesis. We have demonstrated that TGF-β1 reduces Necl-2 mRNA and protein levels at both transcriptional and post-translational levels. Using inhibitor and clathrin shRNA, we have revealed that TGF-β1 induces Necl-2 protein degradation via clathrin-dependent endocytosis. Endocytosis assays further confirmed that TGF-β1 accelerates the internalization of Necl-2 protein to cytosol. Immunofluorescence staining also revealed that TGF-β1 effectively removes Necl-2 from cell-cell interface. In addition, TGF-β1 reduces Necl-2 mRNA via down-regulating Necl-2 promoter activity. Mutational studies coupled with knockdown experiments have shown that TGF-β1-induced Necl-2 repression requires activation of Smad proteins. EMSA and ChIP assays further confirmed that TGF-β1 promotes the binding of Smad proteins onto MyoD and CCAATa motifs in vitro and in vivo. Taken together, TGF-β1 is a potent cytokine that provides an effective mechanism in controlling Necl-2 expression in the testis via Smad-dependent gene repression and clathrin-mediated endocytosis.

Citation: Gao Y, Lui W-Y (2013) Transforming Growth Factor-β1 (TGF-β1) Regulates Cell Junction Restructuring via Smad-Mediated Repression and Clathrin-Mediated Endocytosis of Nectin-like Molecule 2 (Necl-2). PLoS ONE 8(5): e64316. doi:10.1371/journal.pone.0064316

Editor: Effie C. Tsilibary, National Center for Scientific Research Demokritos, Greece

Received November 7, 2012; Accepted April 14, 2013; Published May 31, 2013

Copyright: © 2013 Gao, Lui. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The work was funded by Hong Kong Research Grants Council (HKU773710M) and HKU/CRCG Seed Funding for Basic Research http://www.ugc.edu.hk/eng/r gc/index.htm. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: wylui@hku.hk

Introduction

During spermatogenesis, developing germ cells must migrate from the basal to the adluminal compartment, which requires the disassembly and reassembly of cell junctions between Sertoli cells and developing germ cells [1]. This not only allows progressive movement of developing germ cells along the seminiferous epithelium, but also reattachment of germ cells to adjacent Sertoli cells via cell junctions provides physical support for germ cells. Our and other laboratories have identified several signaling pathways that are involved in the regulation of cell junction restructuring in the testsis. In fact, cross-talk between signaling molecules and different regulatory levels including transcriptional, post-transcriptional and post-translational modification of cell junction proteins mediated by hormones and cytokines are crucial for the precise control of cell junction restructuring [2-4].

Cell junctions between Sertoli and germ cells are constituted by different types of junction protein complexes such as nectin-afadin and JAM-ZO-1 protein complexes [5,6]. Recent animal studies have shown that knockout of individual junction proteins, including nectin-2, nectin-3, or JAM-C cause infertility in male mice, indicating that each of the protein components indeed plays an indispensable role in cell adhesion during spermatogenesis [7-10]. Nectin-like molecule-2 (Necl-2) belongs to immunoglobulin superfamily. It has been also known as IGSF4A/TSLC1/RA175/SgIGSF/SynCAM/CADM1 due to its diverse functions in various tissues [11-16]. Necl-2 contains three immunoglobulin-like loops in the extracellular domain, a transmembrane domain and a cytoplasmic tail. In the testsis, Necl-2 is exclusively expressed by spermatogenic cells. Detailed immunohistochemical analysis has indicated that Necl-2 is expressed in intermediate spermatogonia and step 5-6 spermatids [17]. Recent studies have revealed that Necl-2 is also detected in several type A spermatogonia and step 5-6 spermatids [18]. Necl-2 mediates homophilic interaction between spermatogenic cells, as well as heterophilic interaction between Sertoli and germ cells [17,19]. Studies have confirmed that Necl-2 on spermatogenic cells interacts with Necl-5 (PVR/CD155/Tage4) that is expressed on Sertoli cells [19]. Like other junction proteins, knockout studies have shown that Necl-2 null male mice are sterile, and display defects in spermatogenesis with reduced sperm motility and abnormal morphology of spermatids [20-23]. A significant reduction in the number of mature spermatids has been...
reported in the knockout mice. It is due to severe cell sloughing from the seminiferous epithelium and the disruption of the intercellular cytoplasmic bridge between germ cells. Apparently, Necl-2 is essential for adhesion between spermatogenic cells as well as between Sertoli cells and spermatogenic cells.

Transforming growth factor-β family is known to regulate junction restructuring required for spermatogenesis. For instance, TGF-β1 perturbs the blood-testis barrier (BTB) integrity, the apical ectoplasmic specialization and AJ by altering the expression of TJ and AJ proteins, such as occludin and N-cadherin [24–26]. Recent studies have suggested that TGF-β2 down-regulates JAM-B expression via transcriptional regulation in Sertoli cells [4]. Moreover, it accelerates the internalization of junction molecules such as JAM-A at the cell-cell interface and induces protein degradation via endocytosis [27]. Immunohistochemical analyses reveal that both Sertoli and germ cells express TGF-β1 in rat testes. The level of TGF-β1 is predominant in spermatocytes and early round spermatids at stage VIII and IX of epithelial cycle, and immunoreactivity declines rapidly thereafter [28, 29]. This unique expression pattern of TGF-β1 suggests that it might involve in the regulation of junction dynamics in the testis. In this study, we aim to investigate the potential mechanisms of how TGF-β1 regulates Necl-2 expression in germ cells that may allow timely release of mature germ cells from the epithelium to the lumen by disrupting cell junctions between germ cells. We herein report that TGF-β1 reduces Necl-2 level by Smad-mediated Necl-2 gene repression and clathrin-dependent endocytosis of Necl-2 protein from cell-cell interface.

### Materials and Methods

#### Cells Culture and Treatment

GC-1 spg cells (mouse germ cell line) were obtained from American Type Culture Collection (Manassas, VA). Cells were grown in DMEM (Invitrogen, Carlsbad, CA) containing 10% FBS. Cultures were maintained at 37°C in humidified atmosphere with 5% CO₂ in air. For mRNA stability experiments, cells were pre-treated with actinomycin D (5 ng/ml) and pEGFP vector (0.1 μg) were co-transfected using GeneJuice transfection reagent (Novagen, Madison, WI). Luciferase activity was detected at 48 h post-transfection using a PerkinElmer 2030 multilabel reader (PerkinElmer, Waltham, MA).

#### Antibodies and Reagents

Antibody against Necl-2 (Code No. CM004–3) for Western blotting was obtained from MBL International Corporation (Woburn, MA). Anti-Necl-2 (S4945) for immunofluorescence microscopy was purchased from Sigma-Aldrich (St. Louis, MO).

Anti-Smad2/3 (sc-8332X), anti-Smad4 (sc-7154X), anti-MyoD (sc-760X) and anti-NF-1 (sc-870) antibodies for EMSA were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-Smad3 (Cat no. 51–1500) and anti-Smad4 (sc-79660) for Western blotting were from Zymed Laboratories (South San Francisco, CA) and Santa Cruz Biotechnology, respectively. Antibody against clathrin (Cat no. 610499) was from BD Biosciences (San Jose, CA). Transforming growth factor-β1, actinomycin D (ActD), nystatin, chlorpromazine (CPZ) and MG132 were purchased from Calbiochem (San Diego, CA). Cycloheximide (CHX) was from Sigma-Aldrich.

**Table 1.** siRNAs and shRNAs used for different knockdown experiments in this study.

| Target gene | Sequence (5’-3’) | Catalog no. |
|-------------|-----------------|-------------|
| Smad3 #1    | GAA CUU ACA AGG CGA CAC A | J-040706-05 |
| Smad3 #2    | CCA UGG AGC UCU GUG AGU U | J-040706-07 |
| Smad4 #1    | UCA GGU GGC UGG UCG GAA A | J-040687-05 |
| Smad4 #2    | GCA AAU GAG AGU UGG GUA A | J-040687-07 |
| Clathrin #1 | GAC CAA TCT CAG CAG ACA GTG CCA | TG516542 |
| Clathrin #2 | TCA GTT GCC ACT TAT CAT TGT CTG TCA TC | TG516542 |

doi:10.1371/journal.pone.0064316.t001

**Construction of Necl-2 Promoter-luciferase Plasmids and Site-directed Mutagenesis**

The 5’-flanking region of the Necl-2 gene was generated by PCR amplification using gene-specific primers (Table 2) and mouse genomic DNA. Progressive 5’-deleted regions generated by PCR were cloned into pGL-3 Basic vector (Promega Corp., Madison, WI). Mutant constructs were generated by a three-step PCR mutagenesis using mutagenic primers (Table 2) as described in the previous studies [30]. All plasmids were prepared by Plasmid Midi Kits (Qiagen, Chatsworth, CA) and confirmed by sequencing analysis.

**Semi-quantitative RT-PCR and Quantitative Real-time PCR**

Total RNA was isolated from GC-1spg cells using TRIZOL reagent (Invitrogen) and reverse transcribed with Moloney murine leukemia virus reverse transcriptase kit (Invitrogen). RT products were used as templates for subsequent PCR with a pair of Necl-2 and β-actin primers, respectively (Table 2). Co-amplifications of Necl-2 and β-actin were in their linear phases. The authenticity of the PCR product was confirmed by sequencing analysis. The gel images were captured and analyzed using Quantity One 1-D analysis software (Bio-Rad Laboratories, Hercules, CA). For Real-time PCR, the mRNA level of Necl-2 was analyzed by the 7300 Real Time PCR system (Applied Biosystems, Foster City, CA) with Power SYBR Green Master Mix (Applied Biosystems) according to the manufacturer’s instructions (n = 3, each in triplicate). The GAPDH was used as an internal control for normalization. The specificity of the fluorescence signal was confirmed by both melting curve analysis and agarose gel electrophoresis. The expression level of the target gene was determined using 2⁻ΔΔCₘₚₚ method.

**Transfection and Luciferase Reporter Assays**

GC-1 spg cells (1.3 × 10⁵ cells/cm²) were seeded onto a 12-well plate one day before transfection. Luciferase constructs (0.5 μg) and pEGFP vector (0.1 μg) were co-transfected using GeneJuice transfection reagent (Novagen, Madison, WI). Luciferase activity was detected at 48 h post-transfection using a PerkinElmer 2030 multilabel reader (PerkinElmer, Waltham, MA). pEGFP vector activity was determined by CytoFluor multwell plate reader (PerSeptive Biosystems, Framingham, MA) and used to normalize transfection efficiency. For Smad3/4 knockdown experiment, luciferase constructs (0.5 μg) and pEGFP vector (0.1 μg) were co-transfected with si-Smad3 (20 nM) or/and si-Smad4 (20 nM) using Lipofectamine 2000 transfection reagent (Invitrogen). For shRNA or siRNA experiments, two different target sequences for the gene were used to rule out the off-target effects.
Table 2. Nucleotide sequence of primers used in RT-PCR, plasmid construction, EMSA, ChIP.

| Primer name | Location | Direction | Sequence 5’-3’ | Purpose |
|-------------|----------|-----------|----------------|---------|
| A107        | +285/+304| S         | GAA GGA CAG CAG GTT TCA GC | RT-PCR/ChIP |
| A108        | +702/+721| AS        | CTA GAT AGC GCT GGG TCT GC | RT-PCR/ChIP |
| β-actin     | +314/+337| S         | TCA CCG AGG CCC CTC TGA ACC CTA | RT-PCR |
| β-actin     | +954/+957| AS        | GGC AGT AAT CTC GTT CTG CAT CCT | RT-PCR |
| A141        | −19/−1   | AS        | ATG AAG CTT GTC GGG CAC CTG CCT CAG A | Deletion |
| A142        | −268/−245| S         | ATC AGG GTG AAA GGG AGG CCG AAT TTT AAC GT | Deletion |
| A143        | −502/−477| S         | ATC AGG GTG AAA GGG AGG CCG AAT TTT AAC GT | Deletion |
| A144        | −1029/−1003| S    | ATC AGG GTG TCT GAG ACA CAA CTA AAG TGA GGA CC | Deletion |
| A158        | −459/−140| S         | ATC AGG GTG AAA GGG AGG GGC TAG TCC T | Deletion |
| MP-B        |         | S         | GGA GTA CTA ACC CTG GGC TAG AAT AGG CTG TCC C | Universal primer |
| MP-C        |         | AS        | GGG CCC TTC TTA ATG TTT GTT GC | Universal primer |
| MP-D        |         | S         | GGA GTA CTG ACC CTG GC | Universal primer |
| A174 MYOD*  | AS       | GAG CGA CAC cTC GTG GC | Mutation |
| A175 CCAATa*| AS       | CGG ACA GCT cgg GAG ATG | Mutation |
| A177 CCAATb*| AS       | GAG CGA CAC cTC GTG GC | Mutation |
| A256        |         | S         | TCT GAG GCT GGG GCC CCA C | EMSA |
| A257        |         | S         | GGT GGC CAC CTG CCT CAG A | EMSA |
| A258        |         | S         | TAG CAT CTC ATT AGC TGT CCG CT | EMSA |
| A259        |         | S         | AGG GGA CAG CTA ATG AGA TGC TA | EMSA |
| A287        | −349/−329| S         | GAG AGA CCC GCC TCC TGA AGC | ChIP |
| A288        | −22/−1   | AS        | GTC GCC CAC CTG CCT CAG ACT | ChIP |
| A400        | +242/+261| S         | ACA ACA GCC CCC GCC ACC GG | RT-PCR |
| A401        | +928/+948| S         | GCC CTT GGC CTC GTG GAT CCA | RT-PCR |
| S16         | +15/+38  | S         | TCC GCT GCA GTC CTG TCA AGT CCT | RT-PCR |
| S16         | +376/+399| AS        | GCC AAA CTT CTT GGA TTA TCA GGC | RT-PCR |

Italic base indicates mutated nucleotide. S, sense; AS, antisense. RT-PCR, reverse transcription-polymerase chain reaction; EMSA, electromobility shift assay; ChIP, chromatin immunoprecipitation.

doi:10.1371/journal.pone.0064316.t002

Electrophoretic Mobility Shift Assay (EMSA)

Nuclear extracts were prepared as described previously [4]. Double-stranded oligonucleotides containing MyoD or CCAATa motifs were end-labeled with [γ-32P]ATP (PerkinElmer) by using T4 kinase (Invitrogen). EMSA was performed in 20 μl reaction mixture containing 20 mM HEPES (pH 7.6), 50 mM NaCl, 1.5 mM MgCl2, 1 mM DTT, 1 mM EDTA, 10% glycerol, 1 μg poly (dEdC), radiolabeled probe (100,000 cpm) and nuclear extract (1–15 μg). For competition assay, unlabeled oligonucleotides (100–500×) were added to the reaction as competitors. For supershift assay, EMSA reaction mixture was further incubated with specified antibodies (6 μg) or serum at room temperature for 30 min before gel electrophoresis. The reaction products were separated on a 5% polyacrylamide gel. The gels were dried and scanned and bands were analyzed by Quantity One 1-D analysis software (Bio-Rad).

Western Blotting

Protein extracts from GC-1 spg cells were prepared in IP lysis buffer (30 mM Tris, 0.15 M NaCl, 2 mM EDTA, 2 mM PMSF, 1% NP-40 and 10% glycerol [v/v], pH 7.4 at 22°C). Total protein concentration was determined by Bradford assay (Bio-Rad). Protein extracts were resolved on a polyacrylamide gel, transferred onto nitrocellulose membrane (Bio-Rad) and blocked with 5% non-fat milk powder [w/v] in PBS/Tris/0.1% Tween-20 for 1 h. Membrane was incubated with an appropriate primary antibody at 4°C overnight, followed by incubation of corresponding secondary antibody (Santa Cruz Biotechnology) for 1 h. ECL Western blotting detection reagents (GE Healthcare, Buckinghamshire, UK) were used for protein detection. The X-ray films were scanned and bands were analyzed by Quantity One 1-D analysis software (Bio-Rad).

Chromatin Immunoprecipitation (ChIP) Assay

Chromatin immunoprecipitation (ChIP) assay was conducted using EZ-ChIP kit (Millipore Corp., Billerica, MA). GC-1 spg cells (1.3 × 107 cells/cm2) were seeded onto a 12-well plate. TGF-β1 was added at 18 h before harvest. Lysates were sonicated with Sonifier 450 (Branson, Danbury, CT). Precleared lysates were incubated with antibodies (2 μg) or rabbit serum (2 μg) at 4°C overnight. Protein G agarose with protein/DNA complexes were washed and reversed to free DNA at 65°C for 5 h. DNA was purified using spin columns and analyzed by PCR using specific primers (Table 2).

Endocytosis Assay

GC-1 spg cells (1.3 × 107 cells/cm2) were seeded onto 60-mm dishes 4 days before treatment. Cells were washed twice with ice-cold PBS, incubated with Sulfo-NHS-SS-Biotin (0.5 mg/ml) (Thermo Fisher Scientific, Hudson, NH) in PBS/CM (PBS containing 0.9 mM CaCl2 and 0.33 mM MgCl2) at 4°C for
30 min. Excess biotin was quenched by 50 mM NH₄Cl at 4°C for 15 min. Cells were washed twice with ice-cold PBS and incubated with vehicle or TGF-β1 at 35°C for various time points. Cells were then washed twice with ice-cold PBS, and incubated with biotin stripping buffer (100 mM Tris/HCl, pH 8.6, containing 50 mM NCTA, 100 mM NaCl and 2.5 mM CaCl₂) at 4°C for 30 min and quenched with the quenching buffer (PBS/CIM containing iodoacetamide [5 mg/ml]) at 4°C for 15 min. Cell lysates were harvested in IP lysis buffer (10 mM Tris, pH 7.4, containing 0.15 M NaCl, 2 mM PMSF, 1 mM EGTA, 0.1% NP-40, 1% sodium orthovanadate, leupeptin [1 μg/ml], aprotinin [1 μg/ml] and 10% glycerol [v/v]). Biotinylated proteins were isolated by pre-culturing 700 μg of protein lysate with UltraLink Immobilized NeutrAvidin Plus (Thermo Fisher Scientific) at 4°C overnight. NeutrAvidin resin was washed with IP lysis buffer, and biotinylated proteins were then extracted in SDS sample buffer. Immunoblot analysis was performed to monitor the internalization process of Necl-2.

Immunofluorescence Microscopy

GC-1 spg cells (1.3×10⁴ cells/cm²) were grown on Matrigel-coated coverslips for 4 days. Vehicle or TGF-β1 was added 24 h before harvest. For inhibitor studies, cells were pre-treated with CHX (5 μg/ml, 30 min), followed by H₂O or CPZ (12.5 μg/ml) for 1 h before addition of cytokine. For clathrin knockdown experiment, two different shRNAs (1 μg) were transfected using

Figure 1. Effects of TGF-β1 on Necl-2 expression and localization in GC-1 spg cells. Cells treated with vehicle (4 mM HCl/0.1%BSA) or TGF-β1 (5 ng/ml) were subjected for RT-PCR (A) and Real-time PCR (B) analysis using primer specific for Necl-2 gene. For RT-PCR, β-actin was co-amplified as an internal control. Necl-2 mRNA levels were normalized with β-actin. The authenticity of the PCR product was confirmed by sequencing analysis. For real-time PCR, GAPDH was used as an internal control for normalization. (C) Necl-2 protein level was analyzed by Western Blotting. (D) Immunostaining was performed in vehicle- and TGF-β1-treated cells. Cells were incubated with rabbit anti-Necl-2 antibody, followed by goat anti-rabbit IgG conjugated with FITC. Necl-2 appeared as green fluorescent. DAPI was used for nuclear staining. Scale bar = 20 μm. Results of RT-PCR, real-time PCR and Western blotting are expressed as the mean ± S.D. of three independent experiments. ns, not significant vs vehicle control; *, p<0.01 vs vehicle control; **, p<0.001 vs vehicle control. doi:10.1371/journal.pone.0064316.g001
TGF-β1 Regulates Cell Junction Restructuring

(A) CHX

Vehicle | + | + | + | + | - | - | - | - | - | - | - | -
TGF-β1 | - | - | - | - | + | + | + | + | + | + | + | +
Time (Hour) | 0 | 3 | 12 | 18 | 24 | 3 | 12 | 18 | 24 | 3 | 12 | 18 | 24

Necl-2, ~100 kDa
Actin, 42 kDa

Relative Necl-2 Expression (Arbitrary Unit)

(B) CHX

MG132 (µM) | - | - | 25 | 25 | 50 | 50
Vehicle | + | + | - | - | + | +
TGF-β1 | + | + | + | + | + | +

Necl-2, ~100 kDa
Actin, 42 kDa

Relative Necl-2 Expression (Arbitrary Unit)

(C) CHX

Nystatin (µg/ml) | - | 25 | 25 | 50 | 50
Vehicle | + | + | - | - | + | +
TGF-β1 | - | - | + | + | + | +

Necl-2, ~100 kDa
Actin, 42 kDa

Relative Necl-2 Expression (Arbitrary Unit)

(D) CHX

Pre-treatment | 1 h | 1.5 h
CPZ (µg/ml) | 12.5 | 12.5
Vehicle | + | + | + | + | + | + | + | + | + | + | + | +
TGF-β1 | + | + | + | + | + | + | + | + | + | + | + | +

Necl-2, ~100 kDa
Actin, 42 kDa

Relative Necl-2 Expression (Arbitrary Unit)

(E) Mock vs CPZ (12.5 mg/ml)

Vehicle | + | + | + | + | + | + | + | + | + | + | + | +
TGF-β1 | + | + | + | + | + | + | + | + | + | + | + | +

Necl-2
Necl-2/DAPI

Scale bar: 50 µm
Lipofectamine 2000 transfection reagent (Invitrogen) respectively. At 48 h post transfection, cells were pre-treated with CHX, followed by vehicle/TGF-β1 treatment for 24 h. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.3% Triton X-100 for 20 min. Cells were then washed with PBS and blocked with 10% normal goat serum for 1 h. This is followed by incubation of anti-Necl-2 (1:50) overnight at 4°C. Cells were washed with PBS before incubation with FITC-goat anti-rabbit IgG (Zymed) or Alexa Fluor 555-goat anti-rabbit IgG (Molecular Probes, Eugene, OR) for 1 h. Slides were mounted in Vectashield Hardset with 4′,6′ diamino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA). Images were acquired by Carl Zeiss LSM 710 NLO confocal laser scanning microscope.

**Data Analysis**

Data were shown as means ± S.D. of duplicate assays in three independent experiments for RT-PCR, immunoblot and transfection assays or means ± S.D. of triplicate assays in three independent experiments for real-time PCR. For EMSA and ChIP, all experiments were repeated three times and consistent results were obtained. For time-course experiments, statistical analyses were performed using one-way ANOVA with Tukey’s multiple comparison tests. For all other studies, Student’s t tests were performed using software PRISM (GraphPad Software, Inc., San Diego, CA).

**Results**

**TGF-β1 Reduces Necl-2 in both mRNA and Protein Levels**

Since primary germ cells cannot culture healthy alone for more than 1 day and show low transfection efficiency, we chose to use germ cell line to delineate the molecular mechanism of how TGF-β1 regulates Necl-2 expression. RT-PCR, real-time PCR and Western blotting were performed to check whether TGF-β1 regulates Necl-2 expression in mouse germ cell line GC-1 spg cells. Cells were treated with vehicle or TGF-β1 (5 ng/ml) at specified time points. Both RT-PCR and real-time PCR analyses have shown that TGF-β1 down-regulated Necl-2 mRNA levels in a time-dependent manner (Fig. 1A and Fig. 1B). A time-dependent reduction of Necl-2 protein level was also detected (Fig. 1C). Necl-2 mRNA and protein levels were reduced by 35% and 60% respectively after 24 h TGF-β1 treatment. The reduction of Necl-2 protein levels was further confirmed by immunofluorescence staining on TGF-β1-treated cells. It is apparent that Necl-2 is localized at the cell-cell interface (Fig. 1D, upper panel). Upon TGF-β1 treatment, no fluorescence signal could be detected (Fig. 1D, lower panel), indicating that Necl-2 protein no longer exists at the cell-cell interface. These results clearly suggested that TGF-β1 is a potent negative regulator of Necl-2 expression.

**TGF-β1 Reduces Necl-2 via Post-translational Regulation**

Evidence has shown that post-translational regulation allows rapid turnover of junction proteins at the blood-testis barrier, which enables rapid restructuring of the cell junctions required for progressive movement of developing germ cells in the epithelium [27,31]. Apparently, TGF-β1 reduced Necl-2 protein significantly and rapidly, we wonder if post-translational regulation plays a crucial role in TGF-β1-mediated Necl-2 protein reduction. To test this, cells were pre-treated with cycloheximide (CHX) for 30 min to block protein synthesis, followed by vehicle or TGF-β1 treatment. As shown in Fig. 2A, TGF-β1 remains capable of inducing a significant reduction of Necl-2 protein level (40% reduction) in the presence of CHX when compared with vehicle control. This result suggests that TGF-β1 reduces Necl-2 protein level, at least in part, via promoting the turnover of Necl-2 protein.

**TGF-β1 Promotes Necl-2 Protein Degradation via Clathrin-dependent Endocytosis**

To unravel the TGF-β1-induced Necl-2 protein degradation pathway, various inhibitors were employed to block the proteasome and endocytotic degradation pathways which are the two major mechanisms reported for effective removal of cell junction molecules from cell-cell interface [32]. MG132 (a proteasome inhibitor), nystatin (an inhibitor of caveolin-dependent endocytosis) and CPZ (an inhibitor of clathrin-mediated endocytosis) were used prior to TGF-β1 treatment in order to screen the potential degradation pathway. Pretreatment of two different doses of MG132 (Fig. 2D) or nystatin (Fig. 2C) could not abolish the effect of TGF-β1 on Necl-2 expression, indicating that TGF-β1-induced Necl-2 degradation is not mediated via ubiquitin-proteasome pathway or caveolin-dependent endocytosis. However, significant rebound in Necl-2 protein level was observed when CPZ was employed (Fig. 2D). Apart from the rebound of Necl-2 protein level, re-localization of Necl-2 at the cell-cell interface was observed in CPZ-pretreated cells in TGF-β1-treated group (Fig. 2E). Western blotting analysis and immunofluorescence staining unequivocally suggest that clathrin-mediated endocytosis possibly involves in TGF-β1-induced protein degradation.

To further examine this possibility, two different clathrin shRNAs were used to knockdown clathrin expression separately. Both of these two clathrin shRNAs, but not sh-vector or sh-ctrl construct, effectively reduced clathrin protein level (Fig. 3A). In the parallel experiment, knockdown of clathrin significantly abrogated TGF-β1-mediated Necl-2 reduction (Fig. 3A) as indicated by the rebound of Necl-2 protein level in clathrin shRNA-transfected group, but not in control shRNA one. Immunofluorescence staining has also shown that Necl-2 remained at the cell-cell interface in TGF-β1-treated cells that were transfected with clathrin shRNA constructs, but not ctrl shRNA or sh-vector alone (Fig. 3B). To monitor the internalization process of Necl-2 protein upon TGF-β1 treatment, endocytosis assays were also performed. It is apparent that TGF-β1 significantly induced the internalization of Necl-2 as the level of biotinylated Necl-2 protein in cytosol was significantly increased upon TGF-β1 stimulation when compared to the corresponding control at 15 min and 30 min (Fig. 3C). At 60 min after exposure to TGF-β1, the level of cytosolic biotinylated Necl-2 protein declined accordingly, suggesting that TGF-β1 accelerates the endocytosis of Necl-2,
followed by the degradation of endocytosed Necl-2 protein. Taken together, inhibitor treatment, shRNA approach and endocytosis assays have unequivocally demonstrated that TGF-β1 induces Necl-2 protein degradation via clathrin-dependent endocytosis.

Transcriptional Regulation Plays a Role in TGF-β1-induced Necl-2 reduction

Apart from post-translational regulation, TGF-β1 also reduced Necl-2 mRNA by 35% (Fig. 1A and 1B), suggesting that TGF-β1 reduces Necl-2 protein via its effect on Necl-2 mRNA. To examine if TGF-β1 reduces Necl-2 mRNA level by destabilizing Necl-2 mRNA transcript, cells were pre-treated with actinomycin D for 2 h to block transcription prior to TGF-β1 treatment. RT-PCR and real-time PCR analyses have shown that TGF-β1 caused no significant change on Necl-2 mRNA level in the presence of actinomycin D when compared to vehicle control (Fig. 1A and Fig. 1B). These results suggest that TGF-β1 down-regulates Necl-2 mRNA level is not mediated via altering the stability of Necl-2 transcript. To check whether TGF-β1 reduces Necl-2 mRNA level via gene transcription, a series of luciferase constructs having Necl-2 promoter region in different length were generated. Cells were transfected with pGL-3 or luciferase constructs and treated with vehicle or TGF-β1 for 18 h prior to analyses. It was found that TGF-β1 caused a significant reduction of Necl-2 promoter activity when cells transfected with p(-159/−1)Luc construct (Fig. 4C). Transfection of two other luciferase constructs [p(-268/−1)Luc and p(-502/−1)Luc] showed similar reductions of Necl-2 promoter activities upon TGF-β1 treatment (Fig. 4C), suggesting that the promoter region between nt -159 and -1 contains crucial cis-acting elements that are responsible for TGF-β1-induced Necl-2 gene repression.

MyoD and Two CCAAT Motifs are Required for TGF-β1-mediated Necl-2 Gene Repression

MyoD, CCAATa and CCAATb motifs were identified within the sequence between nt -159 and -1 by computational analyses using MatInspector (Genomatix Software Inc., Ann Arbor, MI) and TFsearch (Parallel Application TRC Laboratory, Japan) (Fig. 4D, upper panel). Mutated luciferase constructs were generated and transfected into the cells followed by TGF-β1 treatment. As shown in Fig. 4D, single mutation of either MyoD, CCAATa or CCAATb motif abolished TGF-β1-induced Necl-2 gene repression. Also, the double and triple mutants exerted similar rebound effect. These results suggest that MyoD, CCAATa and CCAATb motifs might play important roles in TGF-β1-mediated Necl-2 gene repression. It is worth mentioning that concurrent mutation of MyoD, CCAATa and CCAATb caused no Necl-2 promoter activity, suggesting that these three motifs work in concert to drive the basal Necl-2 gene transcription.

TGF-β1-induced Necl-2 Gene Repression Requires the Activation of Smad Signaling Pathway and the Involvement of MyoD and CCAAT Motifs

It is well-known that Smads are classical downstream molecules of TGF-β signaling cascade. To test if Smad proteins were involved in TGF-β1-induced Necl-2 repression, two si-Smad3 and/or si-Smad4 with different target sequences were used (see Table 1) to knockdown the expression of Smad proteins. Co-transfection of si-Smad3 (si-Smad3#1 or si-Smad3#2) and/or si-Smad4 (si-Smad4#1 or si-Smad4#2) with p(-159/−1)Luc abolished TGF-β1-mediated reduction of Necl-2 promoter activity when compared to the corresponding si-buff or si-ctrl (Fig. 4E), suggesting that down-regulation of Necl-2 promoter activity requires Smad proteins. In the parallel experiment, the level of Smad3 and Smad4 proteins after introduction of si-Smad3 and si-Smad4 in cells were examined by immunoblotting (Fig. 4E, upper panel).

To determine the cis-acting motifs involved in TGF-β1/Smads-induced Necl-2 gene repression, overexpression of Smad proteins with p(-159/−1)Luc or its mutant constructs carrying mutation on the respective cis-acting motifs were performed. Transfection of either Smad3 or Smad4 overexpression constructs with wild-type p(-159/−1)Luc construct (Fig. 4C). Transfection of two other luciferase constructs [p(-268/−1)Luc and p(-502/−1)Luc] showed similar reductions of Necl-2 promoter activities upon TGF-β1 treatment (Fig. 4C), suggesting that the promoter region between nt -159 and -1 contains crucial cis-acting elements that are responsible for TGF-β1-induced Necl-2 gene repression.

TGF-β1 Induces the Binding of Smad Proteins to MyoD and CCAATa Motifs in vitro and in vivo

To determine the binding of Smad proteins with the cis-acting motifs, EMSAs were performed. EMSAs have shown that DNA-protein complexes (complexes A–C) were formed dose-dependently when radiolabeled MyoD or CCAATa probes were incubated with increasing amount of nuclear extract, and the specificities of the complexes were confirmed by cold competition assays (Fig. 5A and 5D). Antibody supershift assays indicated that NF-1, but not MyoD or Smad proteins, was the transcription factor bound to MyoD motif in untreated condition (vehicle control) as the formation of complex A diminished in the presence of NF-1 antibody (Fig. 5B). However, a change in the binding component of transcription factors to MyoD motifs upon TGF-β1
TGF-β1 Regulates Cell Junction Restructuring

Figure A: Time (Hour) vs. β-actin and NecI-2 levels for ActD+Vehicle and ActD+TGF-β1 conditions.

Figure B: Time (Hour) vs. NecI-2 mRNA level for ActD+Vehicle and ActD+TGF-β1 conditions.

Figure C: Mouse NecI-2 5' flanking region with luciferase reporter assays for Veh and TGF-β1.

Figure D: CCAATb site with luciferase reporter assays for Veh and TGF-β1.

Figure E: Smad3 and Smad4 knockdown assays with relative promoter activity.

Figure F: pcDNA3.1, Smad3, Smad4, Smad3+Smad4 conditions with relative promoter activity.
treatment was observed. TGF-β1 promoted the binding of Smad3 and Smad4 to the MyoD motif when cells were treated with TGF-β1 (Fig. 5C, lanes 2–4 vs 5B, lanes 1, 4 & 5). For CCAATα motif, two specific DNA-protein complexes (B and C) were observed in vehicle control (Fig. 5D). Apparently, NF-1 was the major component of these complexes when vehicle-treated nuclear extracts were used (Fig. 5E). When TGF-β1-treated nuclear extracts were used, we detected an increase in the formation of complex B and a reduction in the formation of complex C (Fig. 5F, lane 2 vs lane 1), suggesting that complex B might act as a negative regulatory complex. Furthermore, antibody supershift assays showed that Smad3 and Smad4 are the components of complex B when TGF-β1-treated nuclear extracts were used (Fig. 5F, lane 2 vs lanes 3 & 4). These results indicated that NF-1 is the transcription factor that normally binds to the MyoD and CCAATα motifs for basal gene transcription, while TGF-β1 promotes the binding of Smad3 and Smad4 that negatively regulates Necl-2 gene transcription via competitive binding on MyoD and CCAATα motifs. It was different from that in vehicle control where anti-Smad antibodies were not able to diminish the formation of complexes A and B, suggesting that the binding of Smad proteins to these two motifs is TGF-β1-dependent. It is apparent that Smad proteins compete successfully against with NF-1 for MyoD motif and CCAATα motif (complex B) in the presence of TGF-β1, resulting in negative regulation. In addition, TGF-β1 promotes the formation of complex B where Smad proteins binds to, while it partly inhibits the formation of complex C where the positive regulator, NF-1, binds onto (Fig. 5F).

The reduced amount of positive regulator bound to the respective motifs may also serve as another mechanism in mediating gene repression.

Mutational studies have shown that single mutation of CCAATβ motif abolish the effect of TGF-β1 on Necl-2 gene transcription (Fig. 4D), suggesting that CCAATβ motif might also be involved in TGF-β1-mediated Necl-2 gene repression. However, overexpression of Smad proteins coupled with mutational analyses (Fig. 4F) and EMSA performed using CCAATβ probe (data not shown) have demonstrated that the negative regulators (Smad proteins) do not directly interact with CCAATβ motif in triggering TGF-β1-mediated Necl-2 gene repression. Although Smad proteins do not bind to CCAATβ motif, we cannot rule out the possibility that CCAATβ motif may assist Smad proteins bound onto MyoD and CCAATα motifs via its involvement in proper looping of Necl-2 promoter region. In short, there is a functional cooperation between MyoD and CCAATα motifs in initiating TGF-β1-mediated Necl-2 gene repression.

Apart from TGF-β1-mediated Necl-2 gene repression, we also found that TGF-β1 reduces Necl-2 protein level via post-translational regulation. TGF-β1 promotes the degradation of Necl-2 protein appeared on germ cells via clathrin-mediated endocytosis. Both inhibitor (CPZ) treatment (partially rebound in

Discussion

Sertoli cells play crucial roles in paracrine regulation of spermatogenesis by providing growth factors and cytokines to developing germ cells. Besides, physical interactions between developing germ cells and between Sertoli-germ cells via cell junctions in nurturing the development of germ cells as such interaction provides physical and structural support to developing germ cells. Knockout studies indicated that Necl-2 mediates Sertoli-germ and germ-germ cell interactions that are essential for spermatogenesis. Necl-2 null male mice are infertile with defects in spermatozoa [20–23]. Previous study revealed that Necl-2 mRNA could only be detected in spermatogonia and early pre-meiotic spermatocytes [14]. Subsequent studies have found that Necl-2 protein is expressed on type A spermatogonia through to early pachytene spermatocytes, as well as step 5 to late spermatids [17,18]. Researchers have speculated that transcription of Necl-2 terminates in early pre-meiotic spermatocytes, while translation restarts in spermatids using mRNA that was synthesized in per-meiotic germ cells [17]. In this study, we have unraveled the potential mechanism on how Necl-2 transcription is terminated and how Necl-2 protein at the cell-cell interface is internalized and degraded. We found that TGF-β1 is a potent cytokine that mediates transcriptional repression of Necl-2 gene in GC-1 spg cells. Apparent, this could be an effective mechanism to terminate the transcription of Necl-2 gene in early pre-meiotic germ cells. It is of interest to point out that the existing Necl-2 mRNA transcripts remain very stable even after TGF-β1 treatment in the actinomycin D study, which fits the hypothesis that the mRNA synthesized in early stage of germ cell development with long half-life may be used for protein translation in spermatids.

In examining the details of transcriptional mechanism, we found that NF-1 interacts with both MyoD and CCAATα motifs and thus functions as a positive regulator to mediate the transcription of Necl-2 gene in normal condition (vehicle-control). Overexpression of NF-1 showed that NF-1-A and NF-1-B positively regulate Necl-2 gene transcription (Fig.S1). Upon TGF-β1 stimulation, there is a change in the components of transcription factors that bind to MyoD and CCAATα motifs. TGF-β1 indeed activates Smad pathway and promotes the binding of Smad proteins to MyoD and CCAATα motifs. It was different from that in vehicle-control group where anti-Smad antibodies were not able to diminish the formation of complexes A and B, suggesting that the binding of Smad proteins to these two motifs is TGF-β1-dependent. It is apparent that Smad proteins compete successfully against with NF-1 for MyoD motif and CCAATα motif (complex B) in the presence of TGF-β1, resulting in negative regulation. In addition, TGF-β1 promotes the formation of complex B where Smad proteins binds to, while it partly inhibits the formation of complex C where the positive regulator, NF-1, binds onto (Fig. 5F). The reduced amount of positive regulator bound to the respective motifs may also serve as another mechanism in mediating gene repression.
nuclear extract (1–15 μg) alone or in the presence of cold competitors (100- to 150-fold excess). (B–E) Labeled probes were incubated with vehicle or TGF-β1 treated nuclear extract (15 μg for TGFβ motif and 10 μg for CCATa motif) in the presence of specified antibodies or rabbit serum (Rb serum). (G) A schematic drawing illustrating the relative location of MyoD and CCATa cis-acting motifs in the Necl-2 promoter and chromatin immunoprecipitation assay. TGF-β1-treated genomic DNA-protein samples were immunoprecipitated with antibodies against Smad3 and Smad4 (2 μg) or rabbit serum. Precipitated DNA-protein complexes were subjected to DNA purification. The promoter region and the open reading frame of Necl-2 gene were amplified using specific primer pairs no. A287/A288 (for promoter region) and no. A107/A108 (for open reading frame), respectively, followed by agarose gel electrophoresis. Rb, Rabbit. Cpx, complex.

doi:10.1371/journal.pone.0064316.g005

1-μ hr CPZ incubation and completely rebound in 1.5-μ hr CPZ incubation) and shRNA knockdown studies have unequivocally demonstrated the involvement of clathrin in TGF-β1-mediated Necl-2 protein degradation. In addition, endocytosis assays further confirmed that TGF-β1 accelerates the kinetic of Necl-2 internalization and thus leads to Necl-2 degradation. Furthermore, immunofluorescence staining clearly revealed that Necl-2 was significantly declined from cell-cell interface upon TGF-β1 treatment, whereas Necl-2 remained at the cell-cell interface in the cells transfected with clathrin shRNA construct. These data suggest that TGF-β1 might perturb cell-cell interaction via internalizing Necl-2 from cell surface via endocytosis. Although this study was performed in spermatogonial cells, it is of importance as mature germ cell line is not available and primary germ cells cannot be cultured alone to perform in-depth mechanistic studies. Therefore, our current studies provide a blueprint in understanding how TGF-β1 might exert its effect in promoting the detachment of germ cells from seminiferous epithelium via disrupting Necl-2-based cell junction complexes.

In summary, we unraveled two mechanisms by which TGF-β1 exerts its effect on Necl-2 protein expression in germ cells that are crucial for Sertoli-germ and germ-germ cell interaction in spermatogenesis. TGF-β1 promotes the binding of Smad proteins to MyoD and CCATa motifs, causing Necl-2 gene repression. Also, it induces internalization of Necl-2 protein from cell-cell interface via clathrin-dependent endocytosis, thus promoting Necl-2 protein turnover.

Supporting Information

Figure S1 Changes in the mRNA levels of TGF-β1 and Necl-2 in staged seminiferous tubules and effect of NF-1 on Necl-2 promoter activity. pCH vector, pCH-NF-1A and pCH-NF-1B were co-transfected with pG-L-5 or p-159/-1lac construct into GC-1spg cells. pEGFP activity was used to normalize transfection efficiency. Promoter activity was represented as the fold change when compared with pGL-3 vector. Results are expressed as the mean±S．D．of three independent experiments. **, p<0.001 vs pCH vector. (TIF)

Acknowledgments

We sincerely thank Prof．P．ten Dijke for providing us with Smad3 and Smad4 plasmids and Prof．Richard M．Gromostakpi for kindly providing us with pCH vector, NF-1A and NF-1B plasmids.

Author Contributions

Conceived and designed the experiments: WYL, YG. Performed the experiments: YG. Analyzed the data: WYL, YG. Contributed reagents/materials/analysis tools: WYL. Wrote the paper: WYL, YG.

References

1. Cheng CY, Munk JD (2000) Cell junction dynamics in the testis: Sertoli-germ cell interactions and male contraceptive development. Physiol Rev 82: 625–674.
2. Sze KL, Lee WM, Lee WM (2000) Expression of CLMP, a novel tight junction protein, is mediated via the interaction of GATA with the Kruppel family proteins, KLF4 and Sp1, in mouse TM4 Sertoli cells. J Cell Physiol 214: 334–344.
3. Sze KL, Lee WM, Lee WM (2000) Post-transcriptional regulation of CLMP mRNA is controlled by tristetraprolin in response to TNFα via a-Jun terminal kinase signalling. Biochem J 410: 357–363.
4. Wang Y, Lee WM (2009) Oppsitive effects of interleukin-1α and transforming growth factor-beta2 induce stage-specific regulation of junctional adhesion molecule-B gene in Sertoli cells. Endocrinology 150: 2404–2412.
5. Takahashi K, Nakanishi H, Miyahara M, Mandai K, Satoh K, et al. (1999) Necl/PRR: an immunoglobulin-like cell adhesion molecule recruited to cadherin-based adherens junctions through interaction with Afadin, a PDZ domain-containing protein. J Cell Biol 145: 539–549.
6. Razoni G, Martinez-Estrada OM, Orsenigo F, Cordononi M, Citi S, et al. (2000) Interaction of junctional adhesion molecule with the tight junction components ZO-1, cingulin, and occludin. J Biol Chem 275: 20520–20527.
7. Bouchard MJ, Dong Y, McDermott BM, Jr., Lam DH, Brown KR, et al. (2000) Defects in nuclear and cytoskeletal morphology and mesial discordalization in spermatozoa of mice lacking nectin-2, a component of cell-cell adherens junctions. Mol Cell Biol 20: 2863–2873.
8. Mueller S, Rosenquint TA, Takai Y, Bronson RA, Wimmer E (2003) Loss of nectin-2 at Sertoli-germ junctions leads to male infertility and correlates with severe spermatogenic head and midpiece malformation, impaired binding to the zona pellucida, and oocyte penetration. Biol Reprod 69: 1330–1340.
9. Iwashita M, Irie K, Ishizaki H, Tanaka-Okamoto M, Miyoshi J, et al. (2006) Role of cell adhesion molecule nectin-3 in spermatid development. Genes Cells 11: 1125–1132.
10. Gliki G, Ehrer K, Aurand-Lions M, Imhof BA, Adams RH (2004) Spermatic differentiation requires the assembly of a cell polarity complex downstream of junctional adhesion molecule-C. Nature 431: 520–524.
11. Gomyo H, Arai Y, Tanigami A, Murakami Y, Hattori M, et al. (1999) A 2-Mb sequence-ready contig map and a novel immunoglobulin superfamily gene, IGSF4 in the LOH region of chromosome 11q23.2. Genomics 62: 139–146.
12. Kuramochi M, Fukushima H, Nobukuni T, Kanie T, Matuyama T, et al. (2001) TSLC1 is a tumor-suppressor gene in human non-small-cell lung cancer. Nat Genet 27: 427–430.
13. Urase K, Soyama A, Fujita E, Momoi T (2001) Expression of RA175 mRNA, a new member of the immunoglobulin superfamily, in developing mouse brain. Neuroreport 12: 3217–3221.
14. Wakayama T, Ohashi K, Mizuno K, Ieki S (2001) Cloning and characterization of a novel mouse immunoglobulin superfamily gene expressed in early spermatogenic cells. Mol Reprod Dev 60: 136–144.
15. Biederer T, Sara Y, Mozuyahoa M, Atasoy D, Liu X, et al. (2002) SynCAM, a synaptic adhesion molecule that drives synapse assembly. Science 297: 1525–1531.
16. Ito A, Hagiyama M, Oonuma J (2008) Nerve-mast cell and smooth muscle-mast cell interaction mediated by cell adhesion molecule-1, CADM1. J Smooth Muscle Res 44: 83–93.
17. Wakayama T, Kasahara H, Arita H, Kobayashi D, Sai Y, et al. (2003) Expression and functional characterization of the adhesion molecule spermatogenic immunoglobulin superfamily in the mouse testis. Biol Reprod 68: 1755–1763.
18. Maekawa M, Ito C, Toyama Y, Suzuki-Toyota F, Fujita E, et al. (2011) Localisation of RA175 (Cadm1), a cell adhesion molecule of the immunoglobulin superfamily, in the mouse testis, and analysis of male infertility in the RA175-deficient mouse. Andrology 43: 180–181.
19. Wakayama T, Sai Y, Ito A, Kato Y, Kurobo M, et al. (2007) Heterophilic binding of the adhesion molecules poliovirus receptor and immunoglobulin superfamily 4A in the interaction between mouse spermatogenic and Sertoli cells. Biol Reprod 76: 1081–1090.
20. Yamada M, Yoshida M, Williams YN, Fukami T, Kikuchi S, et al. (2006) Disruption of spermatogenic cell adhesion and male infertility in mice lacking TSLC1/GHSF4, an immunoglobulin superfamily cell adhesion molecule. Mol Cell Biol 26: 3610–3624.
21. van der Weyden L, Arens MJ, Chausiaux OE, Ellis PJ, Lange UC, et al. (2006) Loss of TSLC1 causes male infertility due to a defect at the spermatid stage of spermatogenesis. Mol Cell Biol 26: 3595–3609.

22. Surace EL, Strickland A, Hess RA, Gutmann DH, Naughton CK (2006) Tslc1 (nectin-like molecule-2) is essential for spermatocyte motility and male fertility. J Androl 27: 816–825.

23. Fujita E, Kouroku Y, Ozeki S, Tanabe Y, Toyama Y, et al. (2006) Oligo-asthenoteratozoospermia in mice lacking RA175/TSLC1/SynCAM/IGSF4A, a cell adhesion molecule in the immunoglobulin superfamily. Mol Cell Biol 26: 718–726.

24. Lui WY, Lee WM, Cheng CY (2001) Transforming growth factor-beta3 perturbs the inter-Sertoli tight junction permeability barrier in vitro possibly mediated via its effects on occludin, zonula occludens-1, and claudin-11. Endocrinology 142: 1865–1877.

25. Lui WY, Lee WM, Cheng CY (2003) Transforming growth factor-beta3 regulates the dynamics of Sertoli cell tight junctions via the p38 mitogen-activated protein kinase pathway. Biol Reprod 68: 1597–1612.

26. Xia W, Mruk DD, Lee WM, Cheng CY (2006) Differential interactions between transforming growth factor-beta3/TbetaR1, TAB1, and CD2AP disrupt blood-testis barrier and Sertoli-germ cell adhesion. J Biol Chem 281: 16799–16813.

27. Yan HH, Mruk DD, Lee WM, Cheng CY (2008) Blood-testis barrier dynamics are regulated by testosterone and cytokines via their differential effects on the kinetics of protein endocytosis and recycling in Sertoli cells. FASEB J 22: 1945–1959.

28. Teerds KJ, Dorrington JH (1993) Localization of transforming growth factor beta 1 and beta 2 during testicular development in the rat. Biol Reprod 48: 40–45.

29. Lui WY, Lee WM, Cheng CY (2003) TGF-betas: their role in testicular function and Sertoli cell tight junction dynamics. Int J Androl 26: 147–169.

30. Lui WY, Wong EW, Guan Y, Lee WM (2007) Dual transcriptional control of claudin-11 via an overlapping GATA/NF-Y motif: positive regulation through the interaction of GATA, NF-YA, and CREB and negative regulation through the interaction of Smad, HDAC1, and mSin3A. J Cell Physiol 211: 630–640.

31. Xia W, Wong EW, Mruk DD, Cheng CY (2009) TGF-beta3 and TNFalpha perturb blood-testis barrier (BTB) dynamics by accelerating the clathrin-mediated endocytosis of integral membrane proteins: a new concept of BTB regulation during spermatogenesis. Dev Biol 327: 48–61.

32. Lui WY, Cheng CY (2007) Regulation of cell junction dynamics by cytokines in the testis: a molecular and biochemical perspective. Cytokine Growth Factor Rev 18: 299–311.